Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bard gains "promising" balloon tech with Lutonix buy

This article was originally published in Clinica

Executive Summary

CR Bard has acquired drug-eluting balloon developer Lutonix in a deal worth up to $325m, giving it access to the only DEB in US trials for peripheral arterial disease. Bard has paid $225m upfront, and will shell out a further $100m if Lutonix's device gains US FDA premarket approval (PMA). PMA submission is expected in 2014.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel